Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718786 | 0.94 | POLB (0.34) | POLBMAPK1LMNATDP1PGD | |
| SCHEMBL10044837 | 0.88 | LMNA (0.36) | POLBMAPK1LMNA | |
| SCHEMBL10044841 | 0.86 | LMNA (0.35) | POLBMAPK1LMNA | |
| SCHEMBL709410 | 0.82 | LMNA (0.33) | LMNA | |
| SCHEMBL14435464 | 0.81 | POLB (0.37) | POLBMAPK1TDP1PGD | |
| SCHEMBL13247467 | 0.79 | LMNA (0.49) | POLBMAPK1LMNATDP1PGD | |
| SCHEMBL3026389 | 0.78 | POLB (0.42) | POLBMAPK1LMNATDP1PGD | |
| SCHEMBL3030371 | 0.78 | LMNA (0.49) | POLBMAPK1LMNATDP1 | |
| SCHEMBL10044849 | 0.77 | LMNA (0.42) | LMNA | |
| SCHEMBL3310580 | 0.77 | LMNA (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | POLB 2876/4885MAPK1 1809/4885LMNA 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.